221 related articles for article (PubMed ID: 34728726)
1. Evaluation of solid tumor response to sequential treatment cycles via a new computational hybrid approach.
Moradi Kashkooli F; Soltani M
Sci Rep; 2021 Nov; 11(1):21475. PubMed ID: 34728726
[TBL] [Abstract][Full Text] [Related]
2. Metronomic chemotherapy and nanocarrier platforms.
Abu Lila AS; Ishida T
Cancer Lett; 2017 Aug; 400():232-242. PubMed ID: 27838415
[TBL] [Abstract][Full Text] [Related]
3. Role of vascular normalization in benefit from metronomic chemotherapy.
Mpekris F; Baish JW; Stylianopoulos T; Jain RK
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1994-1999. PubMed ID: 28174262
[TBL] [Abstract][Full Text] [Related]
4. Minimal PK/PD model for simultaneous description of the maximal tolerated dose and metronomic treatment outcomes in mouse tumor models.
Terterov IN; Chubenko VA; Knyazev NA; Klimenko VV; Bogdanov AA; Moiseyenko VM; Bogdanov AA
Cancer Chemother Pharmacol; 2021 Nov; 88(5):867-878. PubMed ID: 34351468
[TBL] [Abstract][Full Text] [Related]
5. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
Cruz-Muñoz W; Di Desidero T; Man S; Xu P; Jaramillo ML; Hashimoto K; Collins C; Banville M; O'Connor-McCourt MD; Kerbel RS
Angiogenesis; 2014 Jul; 17(3):661-73. PubMed ID: 24569856
[TBL] [Abstract][Full Text] [Related]
6. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
Kerbel RS; Shaked Y
Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
[TBL] [Abstract][Full Text] [Related]
7. A mathematical model to study low-dose metronomic scheduling for chemotherapy.
Arora G; Bairagi N; Chatterjee S
Math Biosci; 2024 Jun; 372():109186. PubMed ID: 38580078
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic/pharmacodynamic modeling of combination-chemotherapy for lung cancer.
Curtis LT; van Berkel VH; Frieboes HB
J Theor Biol; 2018 Jul; 448():38-52. PubMed ID: 29614265
[TBL] [Abstract][Full Text] [Related]
9. Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.
Benzekry S; Pasquier E; Barbolosi D; Lacarelle B; Barlési F; André N; Ciccolini J
Semin Cancer Biol; 2015 Dec; 35():53-61. PubMed ID: 26361213
[TBL] [Abstract][Full Text] [Related]
10. Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells.
Vives M; Ginestà MM; Gracova K; Graupera M; Casanovas O; Capellà G; Serrano T; Laquente B; Viñals F
Int J Cancer; 2013 Nov; 133(10):2464-72. PubMed ID: 23649709
[TBL] [Abstract][Full Text] [Related]
11. Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers.
Benzekry S; Hahnfeldt P
J Theor Biol; 2013 Oct; 335():235-44. PubMed ID: 23850479
[TBL] [Abstract][Full Text] [Related]
12. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance.
Kareva I; Waxman DJ; Lakka Klement G
Cancer Lett; 2015 Mar; 358(2):100-106. PubMed ID: 25541061
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapeutic Dose Scheduling Based on Tumor Growth Rates Provides a Case for Low-Dose Metronomic High-Entropy Therapies.
West J; Newton PK
Cancer Res; 2017 Dec; 77(23):6717-6728. PubMed ID: 28986381
[TBL] [Abstract][Full Text] [Related]
14. Pilot study of a pediatric metronomic 4-drug regimen.
André N; Abed S; Orbach D; Alla CA; Padovani L; Pasquier E; Gentet JC; Verschuur A
Oncotarget; 2011 Dec; 2(12):960-5. PubMed ID: 22156656
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors.
Qayed M; Cash T; Tighiouart M; MacDonald TJ; Goldsmith KC; Tanos R; Kean L; Watkins B; Suessmuth Y; Wetmore C; Katzenstein HM
Pediatr Blood Cancer; 2020 Apr; 67(4):e28134. PubMed ID: 31876107
[TBL] [Abstract][Full Text] [Related]
16. The use of nanoparticulate delivery systems in metronomic chemotherapy.
Yu DH; Ban FQ; Zhao M; Lu Q; Lovell JF; Bai F; Wang C; Guan YY; Luan X; Liu YR; Fang C; Chen HZ
Biomaterials; 2013 May; 34(16):3925-3937. PubMed ID: 23465835
[TBL] [Abstract][Full Text] [Related]
17. A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells.
Kareva I
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29027915
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis and chemotherapy resistance: optimizing chemotherapy scheduling using mathematical modeling.
Bodzioch M; Bajger P; Foryś U
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2281-2299. PubMed ID: 34050795
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant anthracycline-based vs metronomic chemotherapy vs no medical treatment for dogs with metastatic splenic hemangiosarcoma: A multi-institutional retrospective study of the Italian Society of Veterinary Oncology.
Marconato L; Chalfon C; Finotello R; Polton G; Vasconi ME; Annoni M; Stefanello D; Mesto P; Capitani O; Agnoli C; Amati M; Sabattini S
Vet Comp Oncol; 2019 Dec; 17(4):537-544. PubMed ID: 31251441
[TBL] [Abstract][Full Text] [Related]
20. Castration is a prerequisite for the inhibitory effect of metronomic chemotherapy on the growth of experimental castration-resistant prostate cancer.
Jellvert Å; Åhs D; Olausson J; Franck Lissbrant I; Damber JE; Welén K
Acta Oncol; 2018 Jul; 57(7):895-901. PubMed ID: 29299975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
